Growth Hormone Antagonist Therapies for Neurological Disorders and Veterinary Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of the original patent to develop novel therapies for neurological disorders, veterinary applications, and age-related diseases, expanding the scope of growth hormone antagonist treatments beyond cancer.
Background and Problem Solved
The original patent disclosed a composition for treating cancer and other diseases using a human growth hormone receptor antagonist. However, there remains a need for effective treatments for neurological disorders, veterinary applications, and age-related diseases. This inventive concept addresses these limitations by exploring new applications and use cases for the core technology.
Detailed Description of the Inventive Concept
The new claims describe methods and systems for treating neurological disorders, delivering growth hormone receptor antagonists to target sites, and preventing or treating age-related diseases. These innovative approaches involve conjugating the antagonist with polyethylene glycol molecules, using microneedle arrays for transdermal delivery, and modifying the antagonist for increased efficacy against canine or feline cancers.
Novelty and Inventive Step
The new claims introduce novel and non-obvious applications of the growth hormone receptor antagonist technology, expanding its scope beyond cancer treatment and into new therapeutic areas. The inventive step lies in the identification of new uses and modifications that enable the antagonist to address unmet needs in neurological disorders, veterinary applications, and age-related diseases.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different polyethylene glycol molecules, modifying the antagonist for use in other diseases or conditions, or developing new formulations for oral or injectable delivery. Variations of the microneedle array design could also be explored to optimize transdermal delivery.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of neurological disorders, veterinary medicine, and age-related diseases. The market for these applications is substantial, with a growing need for effective treatments and therapies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and pharmaceutical sciences, specifically focusing on protein engineering, receptor antagonists, and targeted therapeutic compositions for cancer and neurological disorders
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degree in molecular biology or biochemistry, experienced in protein modification, drug delivery systems, and receptor-based therapeutic strategies, familiar with conjugation techniques and drug formulation approaches
Obviousness Rationale
A person having ordinary skill would recognize that the source patent's growth hormone receptor antagonist technology provides a foundational platform for exploring alternative therapeutic applications. The PTD's variations represent predictable extensions of the original patent's core technology by applying known protein engineering and drug delivery techniques to expand treatment modalities. The modifications demonstrate standard approaches in pharmaceutical research for optimizing drug delivery, targeting new disease states, and improving therapeutic efficacy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |